Is Saxenda as Good as Wegovy? A Straight Look at Both Medicines

Are these medicines in the same class, or are they genuinely different?

Both Saxenda and Wegovy belong to the GLP-1 receptor agonist class. GLP-1 is a gut hormone that regulates appetite and slows the rate at which the stomach empties; both medicines mimic it. That shared mechanism is probably why people sometimes assume the results will be similar. They are not, and the gap comes down to two things: the active molecule and the dosing frequency.

Saxenda's active ingredient is liraglutide, given as a daily injection at a maximum dose of 3mg. Wegovy's active ingredient is semaglutide, given once a week, rising to a maintenance dose of 2.4mg. Semaglutide binds more selectively to the GLP-1 receptor and stays active in the body far longer, which is what allows that weekly schedule. The pharmacological difference translates directly into the weight-loss numbers.

It is also worth clearing up a misconception that comes up often: because Wegovy's 2.4mg dose sounds numerically smaller than Saxenda's 3mg, people occasionally assume Saxenda must be the stronger medicine. If you want a thorough explanation of how Saxenda and Wegovy compare as medicines, including why milligrams are not comparable across different molecules, our dedicated page covers the key differences in full. The NHS medicines information for semaglutide and the separate liraglutide entry explain each medicine on its own terms.

What do the trial results show for each medicine?

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. Participants taking semaglutide 2.4mg lost an average of around 15% of their body weight, compared with roughly 2.4% in the placebo group. That is the evidence base behind Wegovy's licensed approval.

Saxenda's pivotal trial evidence, from the SCALE programme, showed average weight loss of around 5–8% over 56 weeks at the 3mg liraglutide dose, meaningful, but materially lower than what semaglutide achieves. NICE, which appraised both medicines, ultimately recommended semaglutide (Wegovy) for NHS use under specific conditions; it did not issue a comparable positive recommendation for liraglutide for weight management. You can read NICE's recommendation for semaglutide at NICE technology appraisal TA875.

Indirect comparisons across these programmes consistently favour semaglutide. There is no large-scale direct head-to-head trial between the two medicines at their licensed weight-management doses, but the direction of every available analysis is the same. A prescriber can talk through what those numbers mean for an individual's starting weight and goals.

Does the injection schedule make a real difference to how people get on?

Yes, and it is worth taking seriously. Saxenda requires a daily injection. Wegovy requires one injection per week. For people who dislike needles, or who find daily routines hard to maintain alongside busy lives, that weekly rhythm can be a genuine advantage. Adherence matters, a medicine that fits into your life is one you are more likely to keep using.

Both medicines share a similar side-effect profile driven by their GLP-1 mechanism: nausea, loose stools, constipation, and indigestion are the most commonly reported effects, usually most noticeable when the dose goes up and tending to settle as the body adjusts. Neither is free of these effects, though individual experience varies widely. Our page on how Wegovy performs in practice goes into more detail on what people typically find.

Storage is also slightly different: both require refrigeration, but specific temperature windows and room-temperature allowances are set out in each medicine's Patient Information Leaflet. Following those instructions matters for keeping the medicine effective.

Saxenda is not available through nume, so what is?

Saxenda holds a UK licence for weight management, but it is not a medicine our pharmacy dispenses. If you have been researching Saxenda, it is worth knowing that the two treatments dispensed by our GPhC-registered pharmacy (Wegovy (semaglutide injection) and Mounjaro (tirzepatide injection)) both have stronger trial evidence for average weight reduction than Saxenda does.

Mounjaro is a dual GIP and GLP-1 receptor agonist, the only one of its kind licensed for weight management in the UK, and the SURMOUNT-5 trial found it produced greater average weight loss than semaglutide 2.4mg in a direct head-to-head comparison. You can read about how Wegovy and Mounjaro compare on our weight-loss treatments overview, and for a closer look at what Wegovy involves, our Wegovy guide covers the dosing schedule, eligibility criteria and what to expect.

For a broader look at how semaglutide works and what it is used for, our semaglutide information page is a useful starting point. If you are nearing your target and want to understand what to do when you reach your goal weight on Wegovy, we have a dedicated page walking through the next steps. If you are ready to find out which treatment a prescriber would consider suitable for you, a free consultation with our clinical team is the natural next step. Every consultation is read the same day by a named, GPhC-registered prescriber (a real clinician, not automated software) and there is no obligation to proceed.